iSpecimen Inc. (NASDAQ:ISPC) Sees Significant Increase in Short Interest

iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) saw a significant growth in short interest in September. As of September 15th, there was short interest totaling 220,722 shares, a growth of 53.3% from the August 31st total of 143,980 shares. Currently, 10.0% of the shares of the stock are sold short. Based on an average daily volume of 2,206,668 shares, the days-to-cover ratio is currently 0.1 days.

iSpecimen Price Performance

NASDAQ ISPC opened at $1.14 on Friday. The firm has a market cap of $2.87 million, a PE ratio of -0.02 and a beta of 1.65. iSpecimen has a one year low of $1.14 and a one year high of $52.00. The stock’s 50 day simple moving average is $1.71 and its 200 day simple moving average is $3.29.

iSpecimen (NASDAQ:ISPC – Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.98) earnings per share for the quarter. The business had revenue of $0.15 million for the quarter. iSpecimen had a negative net margin of 2,445.40% and a negative return on equity of 524.39%.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of iSpecimen in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

View Our Latest Analysis on iSpecimen

iSpecimen Company Profile

(Get Free Report)

iSpecimen, Inc operates a digital marketplace designed to connect life sciences researchers with human biospecimens and related clinical information. Its platform helps researchers identify and request samples such as blood, tissue, and other biological materials from hospitals, laboratories, biobanks, and other healthcare or research organizations.

The company’s services support biospecimen sourcing, patient and donor matching, inventory discovery, order management, and sample logistics.

See Also

Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.